Molecular testing for lung adenocarcinoma: Is it time to adopt a “plasma‐first” approach?

There is growing evidence that plasma cell‐free DNA testing can aid in the diagnosis of targetable alterations at diagnosis in patients with advanced nonsquamous lung carcinoma. A plasma‐first approach will facilitate access to precision medicine, with studies suggesting that nearly 60% of patients could benefit compared with the current approach of tissue profiling alone.